Skip to main content

Talk Bio

Search This Blog

Merck's ADC sac‑TMT gets its first global Phase 3 win ahead of schedule

on May 19, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Merck's TROP2‑directed antibody‑drug conjugate sacituzumab tirumotecan (sac‑TMT) has achieved its first global Phase 3 win in the TroFuse‑005 trial in advanced or recurrent endometrial cancer, showing statistically significant and clinically meaningful improvements in both overall survival (OS) and progression‑free survival (PFS) compared with chemotherapy; the trial was unblinded at an early interim analysis, ahead of schedule, and marks the first positive global Phase 3 result from Merck’s TroFuse program for sac‑TMT, paving the way for regulatory submissions worldwide.

Sources:

Merck Enters into Research and Development Funding Agreement ...

Merck Highlights New Long-Term Data and Advancements Across ...

Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264) - Frontiers

Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination ...

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870 ...

Merck ADC, licensed from China, hits mark in first big global trial

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or R

Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264) - PMC - NIH

A Clinical Study of Sacituzumab Tirumotecan in People With Breast ...

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of O

FDA Grants Breakthrough Therapy Designation to Sacituzumab ...

Merck and Blackstone Enter R&D Funding Agreement for sac-TMT

Merck Enters into Research and Development Funding ...

FDA Grants Breakthrough Therapy Designation to Merck's ...

Co. global trial Malignant neoplasm of endometrium Merck Multiple Sulfatase Deficiency Disease Overall Survival Pharmacotherapy Phase 3 sacituzumab tirumotecan therapeutic autologous dendritic cells TROP2

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Xaira Therapeutics Launches X-Cell: First AI Virtual Cell Model Testing Scaling Laws on Massive Perturbation Data

Xaira Therapeutics announced X-Cell on March 17, 2026, a 4.9-billion-parameter diffusion language model, the largest virtual cell model to date, trained on X-Atlas/Pisces, the largest genome-wide CRISPRi Perturb-seq dataset with 25.6 million perturbed single-cell transcriptomes across seven diverse contexts. 1 2 X-Cell predicts cell responses to genetic perturbations, outperforming existing models by up to five-fold on metrics like Pearson delta, and generalizes zero-shot to unseen biological contexts such as iPSC-derived melanocyte progenitors and primary human CD4+ T cells. 1 2 The model follows power-law scaling dynamics similar to large language models, using a novel diffusion architecture that iteratively refines predictions. 2 Xaira, founded in 2024 with over $1 billion funding, plans to expand X-Atlas to primary cells, organoids, and in vivo perturbations, focusing on inflammatory/immunological diseases and antibody therapeutics. 1 3 A subset of the Pisces dataset and X-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Powered by Blogger

X-Data LLC